Skip to main content

Unable to load price data. Sorry.


Clinical Data, Inc. (NASDAQ:CLDA.DL)

CAPS Rating: No stars

The Company operates business in three reporting segments: Molecular Services, Clinics and Small Hospitals and All Other.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:CLDA.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

markjohn62 (< 20)
Submitted July 18, 2009

Vilazodone should be approved for major depressive disorder, but with a warning label for GI side effects. In addition to treating depression, Vilazodone also treats anxiety, a common concurrent diagnosis. Vilazodone has no sexual side effects as is… More

zzlangerhans (99.72)
Submitted January 21, 2011

OK, vilazodone. PDUFA tomorrow. I've been dubious about this drug before, but it was effective in phase III against placebo. Much better analysts than I have weighed in on either side, and I'm putting the odds of first pass approval at about… More


  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about CLDA.DL.

No one has written a Pitch for CLDA.DL stock yet. Tell us why you think CLDA.DL will outperform or underperform against the market.


Find the members with the highest scoring picks in CLDA.DL.

No players have picked CLDA.DL yet. Tell us why you think CLDA.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CLDA.DL.